Skip to main content
. 2019 Jul 2;12(9):1221–1228. doi: 10.1016/j.tranon.2019.06.001

Figure 1.

Figure 1

Mefloquine inhibits proliferation and reduces cell viability in CML cells and its effects are enhanced when combined with tyrosine kinase inhibitors (TKIs). (A) Mefloquine significantly inhibits proliferation in a panel of CML cell lines: K562, KU812, 32Dp210 (wild-type) and 32Dp210 (T315I) after 24 hours. (B) Mefloquine induces loss of cell viability in all cell lines after 24 hours. Isobologram of combination indices (CI) vs fraction affected (Fa) for 32Dp210 (wild-type) (C) and 32Dp210 (T315I) (D) at combination of imatinib to mefloquine 1:100 and ponatinib to mefloquine 1:1000 respectively at 72 hours. If CI50≪ 1, the combination was synergistic; if CI50 = 1, the combination was additive; if CI50≫ 1, the combination was antagonistic. (E) K562 with imatinib (0.4 μM), KU812 with imatinib (0.3 μM), 32Dp210 (wild-type) with imatinib (0.1 μM) and 32Dp210 (T315I) with ponatinib (5 nM) exhibit further loss of cell viability when combined with mefloquine (5 μM) after 72 hours. Drugs were added simultaneously for combination studies. Data are representative of at least three independent experiments. All error bars as shown are standard deviation. *, P ≪ .05, compared to control or TKI.